Covid out Clinical Trial

Written By :  Isra Zaman
Medically Reviewed By :  Dr. Kamal Kant Kohli
Published On 2022-08-19 03:45 GMT   |   Update On 2022-08-19 03:45 GMT
Published in the New England Journal of Medicine, researchers-led by the University of Minnesota Medical School and School of Public Health- have found that metformin, a commonly prescribed diabetes medication, lowers the odds of emergency department visits, hospitalizations, or death due to COVID-19 by over 40 percent; and over 50 percent if prescribed early in the onset of symptoms. The study also found no positive effect from treatment with either ivermectin or low-dose fluvoxamine.
The study design was simple-patients were randomly assigned to receive one of the three drugs individually, placebo, or a combination of metformin and fluvoxamine or metformin and ivermectin. Although the study was placebo-controlled with exact-matching placebo pills, Dr. Carolyn Bramante, the study's lead author says that 83% of volunteers received medications supported by existing data because of the six-arm design. Each participant received 2 types of pills to keep their treatment assignment masked, for 3 to 14 days of treatment. Each volunteer tracked their symptoms, and after 14 days, they completed a survey.
Advertisement
The clinical trial launched in January 2021 after U of M Medical School researchers identified, through computer modeling and observational studies, that outpatient metformin use appeared to decrease the likelihood of mortality from, or being hospitalized for COVID-19.
Ref:
Dr. Carolyn Bramante, Randomized trial of metformin, ivermectin, and fluvoxamine for Covid-19,New England Journal of Medicine,10.1056/NEJMoa2201662
Full View
Tags:    
Article Source : New England Journal of Medicine,NEJM

Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement/treatment or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2024 Minerva Medical Treatment Pvt Ltd

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Similar News